Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Naomi Nakajima is active.

Publication


Featured researches published by Naomi Nakajima.


International Journal of Radiation Oncology Biology Physics | 2013

Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.

Naomi Nakajima; Masaaki Kataoka; Yoshifumi Sugawara; Takashi Ochi; Sachiko Kiyoto; Shozo Ohsumi; Teruhito Mochizuki

PURPOSE To determine whether volume-based parameters on pretreatment (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer patients treated with mastectomy without adjuvant radiation therapy are predictive of recurrence. METHODS AND MATERIALS We retrospectively analyzed 93 patients with 1 to 3 positive axillary nodes after surgery, who were studied with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for initial staging. We evaluated the relationship between positron emission tomography parameters, including the maximum standardized uptake value, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), and clinical outcomes. RESULTS The median follow-up duration was 45 months. Recurrence was observed in 11 patients. Metabolic tumor volume and TLG were significantly related to tumor size, number of involved nodes, nodal ratio, nuclear grade, estrogen receptor (ER) status, and triple negativity (TN) (all P values were <.05). In receiver operating characteristic curve analysis, MTV and TLG showed better predictive performance than tumor size, ER status, or TN (area under the curve: 0.85, 0.86, 0.79, 0.74, and 0.74, respectively). On multivariate analysis, MTV was an independent prognostic factor of locoregional recurrence-free survival (hazard ratio 34.42, 95% confidence interval 3.94-882.71, P=.0008) and disease-free survival (DFS) (hazard ratio 13.92, 95% confidence interval 2.65-103.78, P=.0018). The 3-year DFS rate was 93.8% for the lower MTV group (<53.1; n=85) and 25.0% for the higher MTV group (≥53.1; n=8; P<.0001, log-rank test). The 3-year DFS rate for patients with both ER-positive status and MTV<53.1 was 98.2%; and for those with ER-negative status and MTV≥53.1 it was 25.0% (P<.0001). CONCLUSIONS Volume-based parameters improve recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive nodes. The addition of MTV to ER status or TN has potential benefits to identify a subgroup at higher risk for recurrence.


Annals of Nuclear Medicine | 2013

Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings

Naomi Nakajima; Yoshifumi Sugawara; Masaaki Kataoka; Yasushi Hamamoto; Takashi Ochi; Shinya Sakai; Tadaaki Takahashi; Makoto Kajihara; Norihiro Teramoto; Motohiro Yamashita; Teruhito Mochizuki


Japanese Journal of Radiology | 2012

Factors affecting the local control of stereotactic body radiotherapy for lung tumors including primary lung cancer and metastatic lung tumors.

Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Naoyuki Nogami; Yoshifumi Sugawara; Toshiyuki Kozuki; Shigeki Sawada; Hiroshi Suehisa; Syuichi Shinohara; Naomi Nakajima; Tetsu Shinkai


Breast Cancer | 2014

Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?

Yasushi Hamamoto; Shozo Ohsumi; Kenjiro Aogi; Syuichi Shinohara; Naomi Nakajima; Masaaki Kataoka; Shigemitsu Takashima


Japanese Journal of Radiology | 2012

Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatment

Yasushi Hamamoto; Masaaki Kataoka; Motohiro Yamashita; Naoyuki Nogami; Yoshifumi Sugawara; Toshiyuki Kozuki; Shigeki Sawada; Hiroshi Suehisa; Syuichi Shinohara; Naomi Nakajima; Tetsu Shinkai


Breast Cancer | 2013

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Yasushi Hamamoto; Shozo Ohsumi; Kenjiro Aogi; Shigemitsu Takashima; Shuichi Shinohara; Naomi Nakajima; Masaaki Kataoka


Breast Cancer | 2013

Impact of aggregate of risk factors for isolated locoregional failure in breast cancer patients treated with mastectomy without radiotherapy

Yasushi Hamamoto; Shozo Ohsumi; Kenjiro Aogi; Shuich Shinohara; Naomi Nakajima; Masaaki Kataoka; Shigemitsu Takashima


Journal of Clinical Oncology | 2017

Volume-based parameters on FDG-PET/CT as early predictors of disease recurrence in postmastectomy breast cancer patients with one to three positive axillary lymph nodes without adjuvant radiotherapy.

Naomi Nakajima; Masaaki Kataoka; Atsushi Nishikawa; Yoshifumi Sugawara; Shinya Sakai; Shozo Ohsumi; Sachiko Kiyoto; Teruhito Mochizuki


International Journal of Radiation Oncology Biology Physics | 2015

Predictive Value of Volume-Based Parameters on Postradiation Therapy 18F-FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma

Naomi Nakajima; S. Taguchi; H. Kanzaki; N. Nishijima; Takashi Ochi; Teruhito Mochizuki


International Journal of Radiation Oncology Biology Physics | 2015

Edema Index on Pretreatment MRI Correlates With Clinical Outcomes in Patients With High Grade Glioma

Naomi Nakajima; S. Taguchi; H. Kanzaki; N. Nishijima; Takashi Ochi; Teruhito Mochizuki

Collaboration


Dive into the Naomi Nakajima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge